What is ADVAGRAF 0.5mg
ADVAGRAF 0.5mg is a prolonged-release oral capsule containing tacrolimus as its active ingredient. Tacrolimus is an immunosuppressant medication primarily prescribed to prevent organ rejection in patients who have undergone kidney, liver, or heart transplantation. By modulating the immune system, it reduces the risk that the body will reject the transplanted organ.
The prolonged-release formulation ensures a gradual release of the drug, allowing once-daily dosing and more stable blood levels. This improves patient adherence and reduces fluctuations in drug concentration, which can help minimize side effects and maintain therapeutic efficacy.
- Active Ingredient: Tacrolimus
- Dosage Form: Hard gelatin capsules, prolonged-release
- Strength: 0.5 mg per capsule
- Packaging: 100 capsules per package (two pouches of 50 capsules each, in blister packs)
- Therapeutic Use: Prevention of transplant rejection (kidney, liver, heart)
- Drug Class: Calcineurin inhibitor immunosuppressant
How to use ADVAGRAF 0.5mg
ADVAGRAF 0.5mg should be taken exactly as prescribed by your transplant specialist or healthcare provider. Proper usage is critical to prevent transplant rejection and reduce the risk of side effects.
- Administration: Take the capsules orally once daily, preferably at the same time each day to maintain consistent blood levels.
- Swallow whole: Do not crush, chew, or open the capsules as this can alter the drug release and absorption.
- Food interaction: The capsules can be taken with or without food, but high-fat meals may affect absorption; try to maintain a consistent diet.
- Monitoring: Regular blood tests are essential to monitor tacrolimus levels and adjust dosage to keep drug levels within the therapeutic range and avoid toxicity.
- Missed dose: If you miss a dose, take it as soon as you remember unless it is close to the next dose. Do not double dose to make up for a missed one.
- Avoid abrupt discontinuation: Stopping tacrolimus suddenly can lead to transplant rejection; always consult your healthcare provider before making any changes.
Mode of Action ADVAGRAF 0.5mg
Tacrolimus, the active substance in ADVAGRAF, works by suppressing the immune system through inhibition of calcineurin, a critical enzyme in T-cell activation. Here's how it works:
- Calcineurin inhibition: Tacrolimus binds to an intracellular protein called FK-binding protein (FKBP-12) to form a complex.
- Block T-cell activation: This complex inhibits calcineurin phosphatase activity, which is essential for the activation of nuclear factor of activated T-cells (NF-AT).
- Reduced cytokine production: Without NF-AT activation, T-cells cannot produce interleukin-2 (IL-2) and other cytokines vital for T-cell proliferation and immune response.
- Immunosuppression: The result is a suppression of cell-mediated immune responses, which lowers the risk of the immune system attacking the transplanted organ.
- Selective action: Tacrolimus selectively targets T-lymphocytes, preserving other immune functions to some degree compared to broader immunosuppressants.
ADVAGRAF 0.5mg Interactions ADVAGRAF 0.5mg
Tacrolimus has several clinically significant drug interactions that may affect its blood levels or increase the risk of adverse effects. Some notable interactions include:
- CYP3A4 inhibitors (e.g., ketoconazole, erythromycin, clarithromycin): These drugs can increase tacrolimus blood levels, raising the risk of toxicity such as nephrotoxicity and neurotoxicity.
- CYP3A4 inducers (e.g., rifampicin, carbamazepine, phenytoin): These may decrease tacrolimus levels, potentially leading to transplant rejection due to inadequate immunosuppression.
- Nephrotoxic agents (e.g., NSAIDs, amphotericin B): Concurrent use can enhance the risk of kidney damage.
- Calcium channel blockers (e.g., diltiazem, verapamil): May increase tacrolimus blood concentrations.
- Grapefruit juice: Can inhibit CYP3A4 enzymes and increase tacrolimus blood levels; should be avoided.
- Other immunosuppressants: Combination with drugs like corticosteroids or mycophenolate mofetil is common but requires close monitoring.
Inform your healthcare provider about all medications and supplements to manage potential interactions effectively.
Dosage of ADVAGRAF 0.5mg
The dosage of ADVAGRAF 0.5mg is individualized based on the type of transplant, patient weight, kidney and liver function, and blood tacrolimus levels. General dosing considerations include:
- Initial dose: Typically ranges from 0.1 to 0.2 mg/kg/day taken once daily, usually starting 12-24 hours after transplantation.
- Maintenance dose: Adjusted according to therapeutic drug monitoring to maintain trough blood levels within the target range.
- Therapeutic blood levels: Usually between 5–15 ng/mL, but targets vary by transplant type and time post-transplant.
- Renal or hepatic impairment: Dose adjustment may be necessary, guided by blood level monitoring.
- Special populations: Pediatric and elderly patients may require dose adjustments due to differences in metabolism.
Possible side effects of ADVAGRAF 0.5mg
While ADVAGRAF effectively prevents organ rejection, it can cause a range of side effects, some of which can be serious. Common and notable side effects include:
- Nephrotoxicity: Kidney damage is a common adverse effect requiring close monitoring of kidney function.
- Neurotoxicity: Symptoms may include tremors, headache, insomnia, seizures, and rarely encephalopathy.
- Infections: Due to immunosuppression, patients are at higher risk of bacterial, viral, and fungal infections.
- Hypertension: High blood pressure can develop during therapy.
- Gastrointestinal disturbances: Nausea, diarrhea, abdominal pain, and constipation.
- Hyperglycemia and diabetes mellitus: Tacrolimus can impair glucose tolerance.
- Electrolyte imbalances: Such as hyperkalemia and hypomagnesemia.
- Others: Hair loss, rash, and malaise.
Immediate medical attention is required if you experience signs of allergic reactions, severe infection, or neurological symptoms.
ADVAGRAF 0.5mg Contraindications ADVAGRAF 0.5mg
ADVAGRAF 0.5mg should not be used in patients with the following conditions or history:
- Known hypersensitivity: Allergy to tacrolimus or any component of the formulation.
- Uncontrolled infections: Active serious infections may worsen due to immunosuppression.
- Severe hepatic impairment: Use with caution as metabolism is primarily hepatic.
- Live vaccines: Contraindicated during tacrolimus therapy due to immunosuppression.
- Pregnancy and breastfeeding: Should be used only if clearly needed and under strict medical supervision due to potential risks.
Storage of ADVAGRAF 0.5mg
Proper storage of ADVAGRAF 0.5mg is essential to maintain its stability and effectiveness:
- Temperature: Store capsules at controlled room temperature between 20°C and 25°C (68°F to 77°F).
- Protection: Keep the capsules in their original blister packaging to protect from moisture and light.
- Keep out of reach of children: To prevent accidental ingestion.
- Do not freeze: Avoid storing in very cold conditions or freezing.
- Expiry: Do not use the medication beyond the expiration date printed on the packaging.
ADVAGRAF 0.5mg features an exceptional active ingredient renowned for its potent effects, comprising Tacrolimus. This powerful formulation provides a superior solution for addressing diverse health concerns. With 0.5mg/Capsule concentration and an easily manageable Capsules (Hard Gelatin)/Prolonged Release, it remains a preferred option for countless individuals seeking effective treatment.
Introduction
All you need to know about ADVAGRAF 0.5mg .
Welcome to Dwaey, specifically on ADVAGRAF 0.5mg page.
This medicine contains an important and useful components, as it consists of Tacrolimus.
ADVAGRAF 0.5mg is available in the market in concentration 0.5mg/Capsule and in the form of Capsules (Hard Gelatin)/Prolonged Release.
HIKMA PHARMACEUTICALS is the producer of ADVAGRAF 0.5mg and it is imported from JORDAN,
The most popular alternatives of ADVAGRAF 0.5mg are listed downward .
-
Active Substance
-
Size
100Õs [50 s (10 s Blister x 5) Pouch x 2]
-
Indications
-
Type
Capsules (Hard Gelatin)/Prolonged Release
-
Company
Frequently Asked Questions
ADVAGRAF 0.5mg should be stored according to the instructions provided by HIKMA PHARMACEUTICALS.
In general, it is recommended to store ADVAGRAF 0.5mg in a cool, dry place, away from direct sunlight
and out of the reach of children.
The duration of treatment with ADVAGRAF 0.5mg may vary depending on the condition being treated
and the guidance of your healthcare provider. It is important to follow the prescribed treatment
plan and continue taking ADVAGRAF 0.5mg for the recommended duration, even if your symptoms improve.
If you have any concerns or questions about the duration of treatment, consult your healthcare provider.
It is important to check with your healthcare provider or read the medication label for specific
instructions regarding alcohol consumption while taking ADVAGRAF 0.5mg. Some medications, including
ADVAGRAF 0.5mg, may have interactions with alcohol that can reduce effectiveness, increase side
effects, or pose other risks to your health. It is best to follow the guidance provided by your
healthcare professional.
If you miss a dose of ADVAGRAF 0.5mg, take it as soon as you remember. However, if it is close
to the time for your next scheduled dose, skip the missed dose and continue with your regular dosing
schedule. Do not take a double dose to make up for a missed one unless advised by your healthcare provider.
No, do not stop taking ADVAGRAF 0.5mg without consulting your healthcare provider, even if your
symptoms improve. It is important to complete the full course of treatment as prescribed. Stopping
the medication prematurely may lead to a relapse or incomplete resolution of the condition. If you
have concerns about the duration of treatment, consult your healthcare provider for guidance.
It is important to consult your healthcare provider before taking ADVAGRAF 0.5mg if you are
pregnant or breastfeeding. They will be able to assess the potential risks and benefits based on your
specific situation. Please note that the safety and suitability of ADVAGRAF 0.5mg during pregnancy
or breastfeeding may depend on the active substance [Active Substance], concentration 0.5mg/Capsule,
and the specific recommendations of HIKMA PHARMACEUTICALS.
The effects of ADVAGRAF 0.5mg on your ability to drive or operate machinery can vary depending on
the active substance [Active Substance], concentration 0.5mg/Capsule, and individual factors.
Some medications may cause drowsiness, dizziness, or other side effects that can impair your judgment
or coordination. It is important to read the medication label or consult your healthcare provider to
understand any potential effects on your ability to perform tasks that require alertness.
The instructions for taking ADVAGRAF 0.5mg with or without food may vary depending on the medication
and the recommendations of HIKMA PHARMACEUTICALS. Some medications may be more effective when taken with
food to enhance absorption or reduce stomach irritation, while others may need to be taken on an empty
stomach for optimal absorption. Read the medication label or consult your healthcare provider for specific instructions.
The use of ADVAGRAF 0.5mg in children or elderly individuals may depend on various factors, including
the specific medication, type Capsules (Hard Gelatin)/Prolonged Release, and the recommendations of HIKMA PHARMACEUTICALS. Some
medications may have specific dosing instructions or precautions for these age groups. Consult your
healthcare provider or read the medication label for information regarding the safe and appropriate use
of ADVAGRAF 0.5mg in children or elderly individuals.
Dwaey
All medical information published on the Dwaey website aims to increase medical awareness and health education among users. However, it is not a substitute for professional medical advice. Always consult with a specialist doctor. We strongly advise against using any information or medicine found on the site without referring to your healthcare provider.
Related Products
0 Comments